Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: Baldwin, one of the Senate’s most liberal members, beat Vukmir, a staunch supporter of President Donald Trump, by double digits, based on unofficial results. Baldwin won a number of counties that Trump took in 2016 when he narrowly carried Wisconsin by less than 1 point. Baldwin said in her victory speech Tuesday that her win sends a “loud and clear message” that people in Wisconsin want a senator who will stand up for them against special interests. Baldwin was an early target for outside conservative groups that spent millions attacking her over the summer. But Baldwin outraised Vukmir 5-to-1 and blanketed the airwaves with ads contrasting her support for the Affordable Care Act with votes Vukmir made in the state Legislature in favor of insurance companies. “Democrats, Republicans and independents sent a loud and clear message tonight that they wanted a senator who works not for the special interests, but someone who works for you,” Baldwin said in her victory speech. Vukmir campaigned as the underdog and urged Republicans who supported Trump to surprise the pollsters like they did in 2016. But Democrats came through for Baldwin in a race that marked the first time in Wisconsin history both major party candidates for U.S. Senate were women. Baldwin had recent history on her side: In the last three midterm elections, no incumbent Wisconsin senator from the party not in the White House lost a re-election bid. Baldwin, 56, won her first local race at age 24 and was elected to the Senate in 2012, beating former Republican Gov. Tommy Thompson, in a year when former President Barack Obama was also on the ballot. Baldwin was the first openly gay person elected to the Senate. Baldwin and Vukmir disagreed on every major issue including health care, immigration, taxes, abortion, national security, gun control and criminal justice. Stephenie Hamen, a 42-year-old artist from Sun Prairie, said she voted for Baldwin, in part as a vote for women’s rights and a vote against Trump. “I don’t know if it was to vent (against the president),” she said. “It’s a way to stand up for women as Americans and be heard. It’s a scary time to be a woman in America. No matter what (Trump) says about being a white man in America, it’s scarier for women and minorities. If the Republicans stay in power, we’re writing a check for that party to do whatever they want. If we continue down that path we have no idea what’s coming next.” While Baldwin campaigned with former President Barack Obama and independent Vermont Sen. Bernie Sanders, Vukmir rallied with Trump and forcefully supported his Supreme Court pick Brett Kavanaugh. Baldwin voted against his confirmation. Baldwin is a supporter of Sanders’ “Medicare for All” bill and ran as a defender of the Affordable Care Act. Baldwin cast Vukmir, a nurse, as the potential deciding vote to repeal the law and its guarantees of insurance for people with pre-existing conditions. Vukmir, 60, focused on Baldwin’s handling of the opioid over-prescription crisis at the Tomah Veterans Affairs Medical Center, saying her inaction let veterans down. But the widow and parents of a veteran who died there has come out in support of Baldwin, cutting television ads to help her and undercutting Vukmir’s criticism. Baldwin recounted the story of her childhood illness that made her an advocate for universal health coverage, while also speaking in detail for the first time about her mother’s struggles with mental illness and prescription drug abuse. Baldwin said that has fueled her fight against opioid abuse. ___ Follow Scott Bauer on Twitter: https://twitter.com/sbauerAP ___ For AP’s complete coverage of the U.S. midterm elections: http://apne.ws/APPolitics
[EX A]: Wisconsin Democratic Sen. Baldwin cruises to second term.

[EX Q]: CES is allowing space for sex tech companies as a one-year trial. At the show, such companies were scattered throughout the health and wellness section, near startups pitching fitness trackers and infrared saunas. Lora DiCarlo, a startup that pushed for changes after organizers revoked its award, showed off its Osé robotic “personal massager.” It’s one of a dozen companies at the show focused on vibrators, lube dispensers and other sex tech products. Founders of these startups say their products are about empowerment and wellness for women, something they say has often been overlooked in tech. The historically male-dominated tech trade show has received criticism in past years for having an all-male lineup of speakers and for previously allowing scantily clad “booth babes,” fostering a “boys’ club” reputation. Besides allowing sex tech, CES organizers brought in an official “equality partner,” The Female Quotient, to help ensure gender diversity. The Female Quotient, which trains companies in equality practices, will hold a conference for women during the four-day show, which opened Tuesday. “It’s been a process,” said Gary Shapiro, the head of the Consumer Technology Association, which puts on CES. It’s been a longer process for many sex tech companies to convince investors that they are part of a growing trend that has enough customers. Much of the push has come from the startups’ female founders and from younger consumers who talk more openly about sexuality. As with other technologies, some exhibitors including Lora DiCarlo had prominent booths at CES, while others such as the wearable vibrator company Crave were tucked away. Crave’s exhibit included a camper with a “Build-a-Vibe-Workshop,” where attendees could get an engraved vibrator to wear around their neck. Sex tech has existed in some form for decades. But the gates really began to open in 2016, said Andrea Barrica, founder of sex education site O.school. That year, several other “fem tech” companies made progress in areas such as menstruation and menopause. Those paved the way for sex tech to grow and get investors interested. “Larger institutions are starting to take note, all the way from VC firms to large Fortune 100 companies,” said Barrica, who recently published the book “Sextech Revolution: The Future of Sexual Wellness.” Large institutions like CES had no choice but to look at sex tech, she said. The journey hasn’t been easy. Sex tech founders, many of them women, recount being turned down by dozens of investors. They faced decency arguments and entrenched corporate standards that equated them with porn. But investors are becoming more receptive, said Cindy Gallop, a former advertising executive turned sex tech entrepreneur and founder of the website MakeLoveNotPorn. “It’s entirely because of our refusal to allow the business world to put us down,” she said. Founders insist that their devices — ranging from vibrators to lube dispensers to accessories — have effects outside the bedroom. “Sexual health and wellness is health and wellness,” said Lora DiCarlo, CEO and founder of the company of the same name. “It does way more than just pleasure. It’s immediately connected to stress relief, to better sleep, to empowerment and confidence.” DiCarlo’s $290 Osé device has gotten $3 million worth of advance sales, bolstered in part by the attention it received after CES organizers overturned a decision by an independent panel of judges to give the vibrator a prestigious Innovation Honoree Award in the robotics and drone category. The organizers, CTA, told the company it reserved the right to rescind awards for devices deemed “immoral, obscene, indecent, profane or not in keeping with CTA’s image.” DiCarlo and other female founders pushed back for banning them but allowing humanoid sex robots meant to serve men the previous year. Following criticism, CES organizers ultimately  reinstated the award and apologized. A few months later, the show announced policy changes such as a dress code to prevent skimpy outfits and new “Innovation for All” sessions with senior diversity officials. Osé began shipping to customers this month. DiCarlo said the company is planning to introduce new devices, including less expensive options. Sex tech companies still face major barriers to growth. Polly Rodriguez, CEO of sexual wellness company Unbound, said the company is profitable and customers are more open about buying products than they once were. But she said she still faces roadblocks advertising on social media, and many traditional investors snub the company. “Things are better, but there’s just still this genuine fear of female sexuality more broadly within the institutional side of technology,” she said. And while Gallop offered to speak at CES, conference organizers declined, saying sex tech was not a part of its conference programming. ___ AP Business Writer Joseph Pisani contributed to this report. ___ AP’s CES coverage: https://apnews.com/Consumerelectronics
[EX A]: Sex tech from women-led startups pops up at CES gadget show.

[EX Q]: The implant operation was performed on Wednesday at the Georges Pompidou European Hospital in Paris, the biomedical firm said in a statement. It said that the male patient was awake and talking and he was being monitored in the intensive care unit. “We are delighted with this first implant, although it is premature to draw conclusions given that a single implant has been performed and that we are in the early postoperative phase”, said Carmat’s CEO, Marcello Conviti. Heart-assistance devices have been used for decades as a temporary solution for patients awaiting transplants, but Carmat’s bioprosthetic product is designed to replace the real heart over the long run, mimicking nature’s work using biological materials and sensors. It is aimed at helping the thousands of patients who die each year while awaiting a donor, and reducing the side-effects associated with transplants. “It’s about giving patients a normal social life with the least dependence on medication as possible,” Alain Carpentier, surgeon and Carmat co-founder, told France 2 television. Carmat estimates around 100,000 patients in the United States and Europe could benefit from its artificial heart, a market worth more than 16 billion euros ($22 billion). “We already had devices of this type but they had a relatively low autonomy. This heart will allow for more movement and less clotting. The study that is starting is being very closely watched in the medical field,” Patrick Nataf, head of heart surgery at Paris Bichat hospital, told BFM TV. France’s Health Minister was quick to tout the operation as a sign of the country’s edge in the field of healthcare. “This news brings great pride to France,” Marisol Touraine told BFM TV. “It shows we are pioneers in healthcare, that we can invent, that we can carry an innovation that will also bring great hope to plenty of people.”  Among Carmat’s competitors for artificial heart implants are privately-held SynCardia Systems and Abiomed, both of the United States. “We’re very happy for them and we wish them the best in their pursuit,” said a spokesman for SynCardia, whose artificial heart is the only one approved both in the United States and the European Union and has been implanted over 1,200 times. The longest a patient has lived with SynCardia’s heart is just under four years. In September, Carmat got the green light from French authorities to test the first human implants of the device on four patients in three hospitals. Earlier this year, it won approval to proceed with human implants in Belgium, Poland, Slovenia and Saudi Arabia. The Paris patient is the first worldwide to be implanted with the device, Carmat said. The patients selected for the trials suffer from terminal heart failure and the success of the device will be judged on whether they survive with the implant for at least a month. Conviti told Reuters last month Carmat hoped to finish human trials of the heart by the end of next year and to obtain approval to market them in the EU by early 2015. The Carmat device, developed by a team of engineers from Airbus parent company EADS, weighs about 900g (around 2 lb)- nearly three times more than an average healthy human heart. It is expected to cost 140,000 to 180,000 euros in Europe. It mimics heart muscle contractions and contains sensors that adapt the blood flow to the patient’s moves. It is powered by external, wearable lithium-ion batteries. Inside the heart, surfaces that come into contact with human blood are made partly from bovine tissue instead of synthetic materials such as plastic that can cause blood clots. Patients that will be implanted with Carmat’s devices are more likely to be men. Heart failure affects more men than women and the sheer size of the artificial heart means it can fit in 86 percent of men but only around 20 percent of women. But Carmat says it could easily manufacture a smaller version to fit the smaller bodies of women as well as patients in India and China. Carmat’s shares have risen five-fold since floating on the Paris stock market in 2010, giving the company a market capitalization of about 436 million euros. ($1 = 0.7315 euros)
[EX A]:
France's Carmat implants its first artificial heart in human.